Eltrombopag (Revolade) 25mg Tablets | Swiss Originator TPO-R Agonist | GLT

Generic Information: Revolade (Switzerland)

Generic name: eltrombopag olamine. Brand: Revolade. Manufacturer: Novartis. Origin: Switzerland (originator). Strength: 25 mg film-coated tablets, 14 tablets per pack. Class: thrombopoietin receptor agonist, a non-peptide small molecule acting on the c-Mpl receptor transmembrane domain.

Eltrombopag was originally discovered through a collaboration involving GlaxoSmithKline and Ligand Pharmaceuticals; global rights transferred to Novartis in 2015. It is now approved in more than 100 countries for ITP and in dozens of countries for severe aplastic anemia.

What Is Revolade?

Revolade is an oral platelet-raising therapy. It is used to treat chronic immune thrombocytopenia (ITP) in adults and children aged 6 years and over who have not responded sufficiently to corticosteroids or immunoglobulins, and severe aplastic anemia (SAA) in patients with an inadequate response to immunosuppressive therapy. It can also support interferon-based hepatitis C treatment by correcting thrombocytopenia.

How Does Revolade Work?

Eltrombopag binds the transmembrane region of the thrombopoietin receptor c-Mpl on bone-marrow megakaryocytes, triggering JAK2/STAT signalling that stimulates megakaryocyte growth and platelet production. Because it occupies a site distinct from the endogenous thrombopoietin binding site, its effect adds to — rather than competes with — the body's natural TPO.

Indications

• Chronic ITP (adults and children ≥6 years) refractory to corticosteroids or IVIG
• Severe aplastic anemia refractory to immunosuppressive therapy
• Thrombocytopenia in chronic hepatitis C to facilitate interferon therapy

Dosage

Adults with ITP typically begin at 50 mg once daily; East Asian patients and those with liver impairment start lower. The dose is adjusted to keep platelets at or above 50 × 10⁹/L, not exceeding 75 mg daily in ITP. Take on an empty stomach, one hour before or two hours after food, and two hours apart from calcium- or mineral-rich meals and supplements.

Side Effects

Common effects are headache, nausea, diarrhoea and fatigue. Serious risks include hepatotoxicity (warranting regular liver function monitoring), thrombosis, and cataract. Platelet counts and liver enzymes should be monitored throughout treatment.

Storage

Store at room temperature (20–25°C), protected from light and moisture, out of children's reach.

Why Choose the GLT?

GLT sources originator Revolade directly through regulated channels and ships worldwide with complete documentation. For buyers who prefer the reference Swiss-manufactured brand with full traceability and Certificate of Analysis, GLT offers reliable multi-country sourcing, cold-chain awareness where needed, and ambient shipping for these oral tablets.

How to Order

To request a quotation for Switzerland-sourced Revolade, contact GLT on WhatsApp +86 15234153837 or email [email protected]. Institutional and individual buyers are both supported, and every order ships with CoA, CPP and batch traceability.

FAQ

Is Revolade available in Switzerland? Yes, Revolade is authorised across the EU/EEA and Switzerland, where Novartis is headquartered.

What is the difference between Revolade and Promacta? They are the identical Novartis originator molecule; only the regional brand name differs.

How long does one pack of 14 tablets last? At a 50 mg daily dose (two 25 mg tablets), a 14-tablet pack lasts seven days; it is typically a starter supply for dose titration.

Does GLT ship Swiss Revolade internationally? Yes, with full export documentation and ambient shipping.